消费医疗行业周报（八）：我国重组胶原蛋白新材料实现溶液、凝胶、固体的剂型全覆盖-20250414

Investment Rating - The industry is rated as "Recommended" based on favorable fundamentals and expectations for the industry index to outperform the benchmark index [2][27]. Core Insights - The report highlights the approval of "Recombinant Type III Humanized Collagen Gel" by Jinbo Biotech, marking a significant advancement in the domestic market for recombinant collagen materials, which now covers various formulations including solutions, gels, and solids [1][22]. - The collagen industry is expected to experience a peak in product approvals between 2025 and 2026, with companies like Juzhi Biotech and Chuangjian Medical making significant progress in their product registrations [24]. - The report emphasizes the high market demand for collagen products, particularly in aesthetic applications, driven by the increasing awareness and acceptance of various filler materials [5][11]. Summary by Sections 1. Collagen Filling Products - Various types of facial injectables are categorized into biodegradable and non-biodegradable fillers, with biodegradable fillers further divided into short-acting and long-acting types [8]. - Collagen is a natural protein found in animal tissues, constituting one-third of total body protein, with a significant presence in the skin [10]. 2. Clinical Research on Collagen - Clinical studies on collagen primarily focus on periorbital rejuvenation and skin revitalization, with a growing need for expanded application areas due to increasing aesthetic demands [11]. - The report notes that the use of collagen for periorbital rejuvenation effectively addresses issues like dark circles and fine lines, showcasing its advantages over other materials [11]. 3. Evaluation of Collagen Injection Fillers - The report evaluates the characteristics of collagen fillers, highlighting their immunogenicity, biodegradability, and biocompatibility, which contribute to their safety and effectiveness in clinical applications [14]. - The report also discusses the regulatory landscape, noting that there are currently nine approved collagen injection products in China, with Jinbo Biotech being the sole domestic producer of recombinant collagen [21]. 4. Market Trends and Future Outlook - The report anticipates a surge in collagen product approvals, particularly for recombinant types, as companies navigate the regulatory landscape and enhance their product offerings [24]. - The introduction of innovative technologies, such as self-assembling collagen, is expected to improve product safety and efficacy, further driving market growth [22].